Salute e Benessere

Sectra's nine-month interim report 2024/2025: The industry's most satisfied…

Nine-month period: May 2024–January 2025 Nine-month period: May 2024–January 2025 Comments from Torbjörn Kronander, President and CEO of Sectra AB "Customer satisfaction is about much more than the products and services we offer—not the least, it is about our corporate culture. We all realize how essential effective IT support is for the important work our customers do for patients and society. This insight inspires us to care a little more. Our consistent top ranking in customer...
PR Newswire
14/03/2025

New BRAVO Study Publication Reinforces Clinical Benefits of BLC in Reducing Risk…

626 patients were included in this study, 313 in each study arm (WLC versus BLC). Outcomes data for BRAVO was measured at a 3-year time point in a predominately high-risk patient population. Median age at diagnosis was 71 years. Median follow-up was 3.7 years. 626 patients were included in this study, 313 in each study arm (WLC versus BLC). Outcomes data for BRAVO was measured at a 3-year time point in a predominately high-risk patient population. Median age at diagnosis was 71 years. Median...
PR Newswire
14/03/2025

The 137th Canton Fair: Strengthening Middle East Trade Ties with Successful…

On February 13, the 137th Canton Fair Promotion Workshop was successfully held in Doha. Ali Saeed Bu Sharbak Al Mansori, the Acting General Manager of the Qatar Chamber (QC), praised the strong Qatar-China relations, noting China's importance as one of Qatar's most important trade partners and the noticeable developments in various fields, especially in economic and trade sectors. He emphasized the significance of the Canton Fair and Qatar Chamber's commitment in fostering business ties and…
PR Newswire
14/03/2025

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China…

Allschwil, Switzerland, March 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba ®(isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 2.5 million milestone payment. David Veitch,...
Nasdaq GlobeNewswire
14/03/2025

Idorsia announces the publication of positive data with daridorexant in patients…

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia and nocturiaIn this study, daridorexant was safe and well tolerated, consistent with the well-documented safety profile observed in the Phase 3 studies in chronic insomnia.The data from the Phase 4 study is published in the Journal of Sleep Research On World Sleep Day, Idorsia unites with...
Nasdaq GlobeNewswire
14/03/2025

Coway's NOBLE 2.0 Air Purifier Series Receives iF Design Award 2025 for Product…

This recognition marks Coway's 18th consecutive year of receiving an iF Design Award, underscoring the company's global leadership in design innovation. This recognition marks Coway's 18th consecutive year of receiving an iF Design Award, underscoring the company's global leadership in design innovation. Some of the lauded features of the NOBLE 2.0 Air Purifier series include the products' refined square tower structure and advanced air purification technologies. Equipped with a four-sided...
PR Newswire
14/03/2025

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024…

○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL.○ UCART20x22 Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025.○ AstraZeneca partnership: R&D activities ongoing on three programs – one...
Nasdaq GlobeNewswire
13/03/2025

Unveiling Pharma Market Potential: DelveInsight's Strategic Insights into the…

The client sought to evaluate MASH prevalence, MASH patient burden, existing and emerging therapies for MASH, and market entry feasibility in China, India, Japan, South Korea, and Southeast Asian nations. Understanding MASH grade- and severity-specific patient pools, treatment adoption, and competitive dynamics was crucial to shaping their market entry and product positioning strategy. The client sought to evaluateMASH prevalence, MASH patient burden, existing and emerging therapies for MASH,...
PR Newswire
13/03/2025

VERZENIO's Market Potential Soars as Demand for CDK4/6 Inhibitors Grows |…

Eli Lilly and Company's VERZENIO (abemaciclib) Overview Eli Lilly and Company's VERZENIO (abemaciclib) Overview VERZENIO (abemaciclib) is a prescription medication used to treat adults with HR-positive, HER2-negative breast cancer that has metastasized (spread to other parts of the body). It is administered orally and is prescribed in combination with an aromatase inhibitor as an initial endocrine-based therapy. Additionally, the drug is being developed for the treatment of prostate cancer...
PR Newswire
13/03/2025

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, March13, 2025(GLOBE NEWSWIRE) --Paris, France, March 13, 2025Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDateNumber of Shares OutstandingTotal number of voting...
Nasdaq GlobeNewswire
13/03/2025

Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2024

Public release of Virbac Consolidated Accounts at 31 December 2024.The Group released its 2024 Consolidated Accounts. The document is available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports”.The accounts were audited by the statutory auditors and examined by the board of directors on March 12, 2025. The report of the statutory auditors is in the process of being issued. Attachments Financial report 2024 - Consolidated accounts...
Nasdaq GlobeNewswire
13/03/2025

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of March 12, 2025(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (March 13, 2025 - 6:00 pm)– As of March 12, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as...
Nasdaq GlobeNewswire
13/03/2025

Virbac: 2024 Annual results

Very strong revenues increase of 13.6% at constant exchange rates, driven by:dynamic organic growth (+7.5%) strategic contribution of our acquisitions (+6.1%)2024 operating income 2at an all-time high of 16.6% of revenues (16.0% excluding acquisitions)up by 1.5 percentage points compared to 2023Positive trend for 2025sales growth expected between 4% and 6% at constant exchange rates and scopeoperating income relatively stable at around 16%,...
Nasdaq GlobeNewswire
13/03/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 13 March 2025 at 16.45 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly or through financial instruments by BlackRock, Inc. and its funds decreased on 12...
Nasdaq GlobeNewswire
13/03/2025

Condom Market to Reach $26.3 billion, Globally, by 2035 at 5.8% CAGR: Allied…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A14187 Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A14187 Prime determinants of growth Government programs encouraging contraception, growing concerns about STIs, and increased sexual health knowledge are the main factors driving the condom business. Particularly in emerging nations, the increased focus on population control and...
PR Newswire
13/03/2025

Coronado Research Announce the Appointment of Nick Littlebury as EVP, Regulatory…

Nick Littlebury commented, "Regulatory Affairs is constantly evolving, and companies continually assess the best way to navigate the regulatory landscape. Coronado's foresight in combining science and technology with humans in the loop is unique. Andrew has assembled an industry-leading team that provides best-in-class solutions across clinical development, market access, medical affairs, and regulatory, integrating technology expertise to optimise the drug development pathway. Artificial…
PR Newswire
13/03/2025

Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to…

The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim's drug discovery programs to enable and accelerate the development of novel therapeutics. The partnership leverages Salipro Biotech's proprietary Salipro ®platform technology, which stabilises membrane proteins in their native forms, enabling their use in drug discovery programs. Boehringer Ingelheim will conduct biophysical and...
Nasdaq GlobeNewswire
13/03/2025

FANCL embracing reusable trend in skincare with Eastman Tritan™ packaging

FANCL fans have been thrilled with the toiro packaging, lauding the high-quality Tritan bottle and its benefits for reusable packaging. FANCL leadership has noted that their customers grew up learning about sustainability, so they're eager to embrace products like toiro. Tritan has proven to be a great material for this product because it delivers both quality packaging and reusability, allowing people to add sustainability to their skin care routine. FANCL fans have been thrilled with the...
PR Newswire
13/03/2025

Blue Earth Therapeutics Reports Key Results from Lutetium (177Lu) rhPSMA-10.1…

− Phase 2 trial design will seek to maximise radiation doses to tumor and extend the duration of therapy, with first metastatic castrate resistant prostate cancer patients expected to enroll this quarter − Phase 2 trial design will seek to maximise radiation doses to tumor and extend the duration of therapy, with first metastatic castrate resistant prostate cancer patients expected to enroll this quarter OXFORD, United Kingdom , March 13, 2025 /PRNewswire/ -- Blue Earth...
PR Newswire
13/03/2025

LenioBio Earns Prestigious EU STEP Seal: A Signal of Excellence for Investors

The STEP Seal is a new initiative from the European Commission, designed to spotlight projects and technologies with clear strategic value for Europe and support further investments. This recognition reinforces LenioBio's leadership in transforming biomanufacturing. It demonstrates that the company's technology has met stringent evaluation standards, marking it as a compelling and timely investment opportunity in the strategic healthcare arena. The STEP Seal is a new initiative from the...
PR Newswire
13/03/2025

Trading in GN Store Nord shares by board members, executives and associated…

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them. Details of the person discharging managerial responsibilities/person closely associated NameLise Skaarup Mortensen Reason for the notification Position/statusMember of the Board of Directors...
Nasdaq GlobeNewswire
13/03/2025

Vanotech Appoints Matthew Schiller to Lead Business Development

“Matt's broad-based experience in strategic business development will be critical in driving the next phase of growth for Vanotech,” said Avner Ingerman, M.D., President and Chief Medical Officer of Vanotech. “We are thrilled to welcome Matt to Vanotech and look forward to his leadership as we continue to advance our pipeline of transformative medicines.”Mr. Schiller brings with him over two decades of biopharma business development experience with his most recent role serving as Head of...
Nasdaq GlobeNewswire
13/03/2025

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate…

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate UpdateLandmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercializationACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and tolerability data in Down syndrome (DS) cohort; further interim results in Alzheimer's disease (AD) and DS expected in 2025...
Nasdaq GlobeNewswire
13/03/2025

SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a…

Paul Yang, M.D., Ph.D., Chief of the Paul H. Casey Ophthalmic Genetics Division at Oregon Health & Science University Casey Eye Institute and Principal Investigator of Phase 1/2 ASTRA Study, commented: "Stargardt disease is a devastating inherited retinal disorder with no approved treatments available. The initiation of this study with the dual AAV vector gene therapy, SB-007, represents a critical advancement in finding a potential treatment option for patients with this disease. It is…
PR Newswire
13/03/2025
Altri  Comunicati